Trifluridine, a drug that is currently in clinics for the management of refractory colorectal cancer inhibits spheroid formation in CD133+ DLD1 colorectal cancer cells, suggesting a potential mechanism for its anti-cancer activity [277]. This evidence concerns the gene PROM1 and colorectal cancer.